Shares of Novavax declined after the company reaffirmed full-year revenue and fellow vaccine maker Moderna lowered its guidance. Novavax stock was down 7.3%, to $8.64, on Monday but is up about 89% ...

Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations. The medical-device company's stock was up 16%, to $3.83, ...

Shares of SI-BONE were higher after the medical-device company released some preliminary financial results for the fourth quarter and full year 2024. The company's shares were up 19%, to $16.34, by ...

Alnylam Pharmaceuticals stock advanced after the company said its preliminary 2024 product revenue rose 34%. The shares rose 8% to $256.87 Monday. They are up 37% over the past 12 months.

U.S. Treasury yields have soared over the past week, propelling the 10-year rate to the brink of the 5% mark rarely seen ...

The stronger-than-expected December jobs report spelled trouble for small-cap stocks, according to strategists at Bank of America Global Research. Economists at Bank of America Global Research said ...

While Tom Brady and author Jim Murphy were surprised to see Brown reading the book on the bench, the wide receiver said he ...

Options traders are going bottom-fishing for bonds. It is a risky move, but one that could — with a bit of luck — potentially ...

Investors remain on edge about policy uncertainty a week before President-elect Donald Trump's inauguration promises to bring ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Sarepta Therapeutics exceeded 2024 net product revenue guidance and reaffirmed its 2025 outlook, partly due to strong growth for Duchenne muscular dystrophy drug Elevidys.